Suppr超能文献

非同一人类诱导多能干细胞之间的微细胞介导染色体转移

Microcell-mediated chromosome transfer between non-identical human iPSCs.

作者信息

Uno Narumi, Miyamoto Hitomaru, Yamazaki Kyotaro, Egawa Masaya, Kobayashi Hiroaki, Kazuki Kanako, Osaki Mitsuhiko, Suzuki Teruhiko, Hamamichi Shusei, Oshimura Mitsuo, Tomizuka Kazuma, Kazuki Yasuhiro

机构信息

Laboratory of Bioengineering, Faculty of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.

Department of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

出版信息

Mol Ther Nucleic Acids. 2024 Nov 5;35(4):102382. doi: 10.1016/j.omtn.2024.102382. eCollection 2024 Dec 10.

Abstract

Microcell-mediated chromosome transfer (MMCT) is anticipated as a unique strategy to manipulate numbers of chromosomes, including the generation of hyperaneuploidy syndrome models with human induced pluripotent stem cells (hiPSCs). Mouse A9/Chinese hamster ovary (CHO) cell libraries of human monochromosomal hybrids as chromosome donor cells frequently exhibit chromosomal rearrangement in the components. The generation of a new A9/CHO library is time-consuming and laborious. Here, we developed an MMCT method using hiPSCs as chromosome donor and recipient cells, through micronucleation using paclitaxel and reversine. Membrane fusion during the MMCT was mediated through interactions between the ecotropic viral envelope transiently expressed in chromosome donor cells and mCAT-1 in chromosome recipient cells. This approach involved tagging Chr21 and ChrY by CRISPR-Cas9 and transferring human/mouse artificial chromosomes, Chr21, ChrX, and ChrY, wherein there are no previous reports demonstrating a full-length introduction. Thus, a strategy that combing CRISPR-Cas9-mediated chromosome tagging and MMCT from hiPSCs as chromosome donor cells to hiPSCs as recipient cells systematically produced isogenic disease model hiPSCs with hyperaneuploidy. This approach allows the study of rare diseases and promises to provide new insights into early developmental mechanisms by introducing a comprehensive set of influential chromosomes/regions into hiPSCs.

摘要

微细胞介导的染色体转移(MMCT)被认为是一种独特的策略,可用于操纵染色体数量,包括利用人类诱导多能干细胞(hiPSCs)生成超二倍体综合征模型。作为染色体供体细胞的人类单染色体杂种的小鼠A9/中国仓鼠卵巢(CHO)细胞文库在其组成部分中经常出现染色体重排。构建一个新的A9/CHO文库既耗时又费力。在此,我们开发了一种MMCT方法,使用hiPSCs作为染色体供体细胞和受体细胞,通过紫杉醇和雷弗菌素诱导微核形成。MMCT过程中的膜融合是通过染色体供体细胞中瞬时表达的嗜亲性病毒包膜与染色体受体细胞中的mCAT-1之间的相互作用介导的。该方法涉及通过CRISPR-Cas9对21号染色体和Y染色体进行标记,并转移人类/小鼠人工染色体21号染色体、X染色体和Y染色体,此前尚无关于全长导入的报道。因此,一种将CRISPR-Cas9介导的染色体标记与从作为染色体供体细胞的hiPSCs到作为受体细胞的hiPSCs的MMCT相结合的策略,系统地产生了具有超二倍体的同基因疾病模型hiPSCs。这种方法有助于对罕见疾病进行研究,并有望通过将一整套有影响的染色体/区域导入hiPSCs,为早期发育机制提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c5/11616053/c01572c751a1/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验